维多利祖马布在性结肠炎中含有和不含西奥普林的血清最低度:前性VIEWS药理学研究
Thanaboon Chaemsupaphan1,2, Aviv Pudipeddi1,3, Hui-Yu Lin1,4
1Department of Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney 2139, New South Wales, Australia.
World journal of gastroenterology
|January 15, 2025
概括
维多利祖马布水平与性结肠炎缓解相关. 提奥普林戒药可能需要更高的维多利祖马布剂量来维持缓解,这突出了治疗药物监测的好处.
科学领域:
- 胃肠病学 胃肠病学
- 药理动力学 药理动力学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症疾病,需要持续管理.
- 有限的数据存在于维护治疗UC期间的vedolizumab药理动力学.
- 氨酸对UC患者vedolizumab水平的影响尚不清楚.
研究的目的:
- 检查维多利祖马布暴露与UC患者临床结果之间的关系.
- 评估提奥普林戒断对维多利祖马布度和缓解率的影响.
- 为了确定潜在的vedolizumab血清最低度值,以持续缓解.
主要方法:
- 对UC患者前性随机 VIEWS临床试验的后期分析.
- 在维多利祖马布维持治疗的患者中随机取消蒂奥普林.
- 在48周内监测vedolizumab最低度,抗vedolizumab抗体和临床结果.
主要成果:
- 维多利祖马布的最低度在48周内保持稳定,不论是否使用了提奥普林.
- 在研究群体中没有检测到抗维多利祖马布抗体.
- 在48周内,较高的维多利祖马布最低度与持续的临床缓解有关 (值>11.3微克/毫升).
- 提奥普林的戒断与需要更高的vedolizumab度来维持缓解有关.
结论:
- 在vedolizumab水平和UC结果之间存在积极的暴露-反应关系.
- 治疗药物监测vedolizumab可以提高治疗疗效.
- 虽然 thiopurines 不会影响 vedolizumab 的水平,但它们的取消可能需要调整剂量以保持缓解.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153